Genomic aberrations of the PTEN tumour suppressor gene are among the most common in
prostate cancer. Inactivation of PTEN by deletion or mutation is identified in∼ 20% of …

Purpose: Analytically validated assays to interrogate biomarker status in clinical samples are
crucial for personalized medicine. PTEN is a tumor suppressor commonly inactivated in …

PTEN loss is a promising prognostic and predictive biomarker in prostate cancer. Because it
occurs most commonly via PTEN gene deletion, we developed a clinical-grade, automated …

Objectives To determine whether PTEN status in prostate biopsy represents a predictor of
intermediate and long‐term oncological outcomes after radical prostatectomy, and whether …

Background: PTEN gene loss occurs frequently in castration-resistant prostate cancer
(CRPC) and may drive progression through activation of the PI3K/AKT pathway. Here, we …

Inactivating PTEN mutations are commonly found in prostate cancer, resulting in an
increased activation of Akt. In this study, we investigate the role of PTEN deletion and protein …

PTEN deletion is an established prognostic biomarker in prostate cancer. We compared
PTEN immunohistochemistry (IHC) and PTEN fluorescence in situ hybridization (FISH) in the …

PTEN haploinsufficiency is common in hormone‐sensitive prostate cancer, though the
incidence of genomic deletion and its downstream effects have not been elucidated in …

Prostate cancer (CaP) is characterized by the accumulation of both genetic and epigenetic
alterations that transform premalignant lesions to invasive carcinoma. However, the …

Abstract Background Prostate cancer (PCa), a leading cause of cancer death in North
American men, displays a broad range of clinical outcome from relatively indolent to lethal …